The recognition of the PI3K/AKT/mTOR pathway as a key regulator of hypoxia‐induced EMT and drug resistance in various cancers underscores the importance of targeting this pathway to improve treatment outcomes and overcome therapeutic challenges. This evidence concerns the gene PIK3CD and cancer.